Summarized by Masters of Longevity from PR Newswire.
A preview of a company scientific program showing upcoming clinical and biomarker presentations on movement disorders, highlighting trial designs and exploratory research.
Key Takeaways
- The Phase III MASCOT trial enrolled 401 participants with clinically probable or established multiple system atrophy and will report baseline characteristics.
- MASCOT is a 72-week randomized, double-blind trial comparing two amlenetug doses against placebo with an optional open-label extension.
- Lundbeck reported Phase Ib open-label data for oral dopamine agonist Lu AF28996 in advanced Parkinson's disease and complementary primate preclinical findings.
